Hanmi Pharm’s targeted lung cancer treatment is indicated as the FDA’s Breakthrough Therapy

Hanmi Pharm announced on the 21^st that the US FDA selected HM61713(BI code name: BI1482694), developed by Hanmi Pharm, as the ‘breakthrough therapy’ of lung cancer. HM61713 is a targeted lung cancer treatment in which Hanmi Pharm established a global license agreement(excluding Korea, China and Hong Kong) with Boehringer Ingelheim, a German pharmaceutical company, last July.

The FDA’s Breakthr...